PT - JOURNAL ARTICLE AU - Henrik Salje AU - Cécile Tran Kiem AU - Noémie Lefrancq AU - Noémie Courtejoie AU - Paolo Bosetti AU - Juliette Paireau AU - Alessio Andronico AU - Nathanaël Hozé AU - Jehanne Richet AU - Claire-Lise Dubost AU - Yann Le Strat AU - Justin Lessler AU - Daniel Levy Bruhl AU - Arnaud Fontanet AU - Lulla Opatowski AU - Pierre-Yves Boelle AU - Simon Cauchemez TI - Estimating the burden of SARS-CoV-2 in France AID - 10.1101/2020.04.20.20072413 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.20.20072413 4099 - http://medrxiv.org/content/early/2020/04/27/2020.04.20.20072413.short 4100 - http://medrxiv.org/content/early/2020/04/27/2020.04.20.20072413.full AB - France has been heavily affected by the SARS-CoV-2 epidemic and went into lockdown on the 17th March 2020. Using models applied to hospital and death data, we estimate the impact of the lockdown and current population immunity. We find 2.6% of infected individuals are hospitalized and 0.53% die, ranging from 0.001% in those <20y to 8.3% in those >80y. Across all ages, men are more likely to be hospitalized, enter intensive care, and die than women. The lockdown reduced the reproductive number from 3.3 to 0.5 (84% reduction). By 11 May, when interventions are scheduled to be eased, we project 3.7 million (range: 2.3-6.7) people, 5.7% of the population, will have been infected. Population immunity appears insufficient to avoid a second wave if all control measures are released at the end of the lockdown.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge financial support from the Investissement d’Avenir program, the Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases program (Grant ANR-10-LABX-62-IBEID), Santé Publique France, the INCEPTION project (PIA/ANR-16-CONV-0005) and European Union V.E.O and RECOVER projects. HS would also like to acknowledge support from the European Research Council (No. 804744).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data than can be made available will be put on a GitHub link